Erlotinib

The treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen.